- Home
- RARE vs CNXC Comparison
RARE vs CNXC Comparison
Compare RARE & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | CNXC |
|---|---|---|
| Founded | 2010 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | CNXC |
|---|---|---|
| Price | $34.86 | $41.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $85.20 | $69.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 11-04-2025 | 01-14-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | N/A | ★ 54.10 |
| EPS | N/A | ★ 4.74 |
| Revenue | $630,598,000.00 | ★ $9,720,870,000.00 |
| Revenue This Year | $19.09 | $4.00 |
| Revenue Next Year | $20.62 | $3.16 |
| P/E Ratio | ★ N/A | $8.77 |
| Revenue Growth | ★ 20.63 | 3.40 |
| 52 Week Low | $25.81 | $31.63 |
| 52 Week High | $46.50 | $66.00 |
Technical Indicators
Market Signals| Indicator | RARE | CNXC |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 61.66 |
| Support Level | $32.64 | $38.40 |
| Resistance Level | $36.81 | $40.02 |
| Average True Range (ATR) | 1.60 | 1.31 |
| MACD | -0.29 | 0.59 |
| Stochastic Oscillator | 28.83 | 79.22 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CNXC Concentrix Corporation
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.